AMPLIA THERAPEUTICS LTD(ATX.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

ATX.AU AMPLIA THERAPEUTICS LTD

Not Yet Opened 01-05 16:12:00 AEDT

0.17

+0.00

0.00%

High0.18	Low0.17	Vol1.68M
Open0.18	D1 Closing0.17	Amplitude8.82%
Mkt Cap87.22M	Tradable Cap59.72M	Total Shares513.07M
T/O290.19K	T/O Rate0.48%	Tradable Shares351.32M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ATX.AU","market":"AU","secType":"STK","nameCN":"AMPLIA THERAPEUTICS LTD","latestPrice":0.17,"timestamp":1767589920000,"preClose":0.17,"halted":0,"volume":1676354,"delay":0,"nameEN":"AMPLIA THERAPEUTICS LTD","floatShares":351321835,"shares":513071629,"eps":-0.020164,"marketStatus":"Not Yet Opened","change":0,"latestTime":"01-05 16:12:00 AEDT","open":0.18,"high":0.18,"low":0.165,"amount":290185,"amplitude":0.088235,"askPrice":0.175,"askSize":78671,"bidPrice":0.165,"bidSize":21030,"shortable":3,"etf":0,"ttmEps":-0.020164,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1767654000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.17,"openAndCloseTimeList":[[1767567600000,1767589200000]],"volumeRatio":1.099613,"lotSize":1,"tradeCurrency":"AUD"},"requestUrl":"/m/hq/s/ATX.AU/wiki","defaultTab":"wiki","newsList":[{"id":"2593413368","title":"Amplia Therapeutics Announces Phase 2a Results for Narmafotinib in Metastatic Pancreatic Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2593413368","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593413368?lang=en_us&edition=fundamental","pubTime":"2025-12-23 21:45","pubTimestamp":1766497512,"startTime":"0","endTime":"0","summary":"Amplia Therapeutics Limited has announced that its Chief Medical Officer, Dr. Jason Lickliter, will present updated results from the ongoing ACCENT trial at the 2026 ASCO Gastrointestinal Cancers Symposium, scheduled for January 8-10, 2026, in San Francisco. The poster, titled \"Narmafotinib  in combination with gemcitabine and nab-paclitaxel as first-line treatment for patients with metastatic pancreatic cancer : Phase 2a results,\" will be presented on Friday, January 9, 2026. The full abstract will be published at 5pm US ET on January 5, 2026. Narmafotinib  is a focal adhesion kinase  inhibitor being evaluated in combination with chemotherapy for metastatic pancreatic cancer. The company is also conducting studies of narmafotinib with FOLFIRINOX in advanced pancreatic cancer patients in Australia and the United States.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nNDL8h9HNh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4585","BK4112","LU0314104364.USD","LU2095319765.USD","SG9999014005.SGD","BK7067","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4588","SG9999014021.USD","ATX.AU","LU2210149790.SGD","LU2210150020.SGD","SG9999014013.SGD","SG9999014039.USD","NDAQ","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2592160049","title":"BRIEF-Amplia Enters Into Second Agreement With Korean Drug Screening Company Next&Bio","url":"https://stock-news.laohu8.com/highlight/detail?id=2592160049","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592160049?lang=en_us&edition=fundamental","pubTime":"2025-12-19 22:25","pubTimestamp":1766154334,"startTime":"0","endTime":"0","summary":"BRIEF-Amplia Enters Into Second Agreement With Korean Drug Screening Company Next&Bio Dec 19 (Reuters) - Amplia Therapeutics Ltd ATX.AX:AMPLIA ENTERS INTO SECOND AGREEMENT WITH KOREAN SPECIALIST DRUG ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nTUA357RCR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATX.AU","BK7067"],"gpt_icon":0},{"id":"2592016715","title":"Amplia Enters Into Second Agreement With Korean Specialist Drug Screening Company Next&Bio to Explore Combination Therapy With Fak Inhibitor and Kras Inhibitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2592016715","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592016715?lang=en_us&edition=fundamental","pubTime":"2025-12-19 21:45","pubTimestamp":1766151900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nTUA357RCR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ATX.AU"],"gpt_icon":0},{"id":"2592136767","title":"Amplia Therapeutics Enters Second Phase of Research Collaboration with South Korean Preclinical Drug Screening Firm","url":"https://stock-news.laohu8.com/highlight/detail?id=2592136767","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592136767?lang=en_us&edition=fundamental","pubTime":"2025-12-19 09:54","pubTimestamp":1766109250,"startTime":"0","endTime":"0","summary":"Amplia Therapeutics  entered into the second phase of a research collaboration with South Korean preclinical drug screening company Next & Bio, according to a Friday Australian bourse filing.The firms are collaborating on investigating the ability of Amplia's FAK inhibitors to suppress the growth of patient-derived pancreatic cancer cells that possess genetic mutations in the kRAS gene, which are known to be present in over 90% of pancreatic cancers.Amplia's FAK inhibitor narmafotinib showed promising activity in initial tests, per the filing. Further studies investigating the activity of a combination of narmafotinib with known inhibitors of the mutant kRAS gene will be conducted.Its shares rose 2% in recent trading on Friday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ATX.AU","BK4539","BK7067","LENZ","BK4007"],"gpt_icon":0},{"id":"2591603387","title":"Is Amplia Therapeutics (ASX:ATX) In A Good Position To Deliver On Growth Plans?","url":"https://stock-news.laohu8.com/highlight/detail?id=2591603387","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591603387?lang=en_us&edition=fundamental","pubTime":"2025-12-16 07:28","pubTimestamp":1765841309,"startTime":"0","endTime":"0","summary":"Just because a business does not make any money, does not mean that the stock will go down. For example, although...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-atx/amplia-therapeutics-shares/news/is-amplia-therapeutics-asxatx-in-a-good-position-to-deliver","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-atx/amplia-therapeutics-shares/news/is-amplia-therapeutics-asxatx-in-a-good-position-to-deliver","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ATX.AU","BK7067"],"gpt_icon":0},{"id":"2590501763","title":"Amplia Therapeutics Reports 35% Response Rate in ACCENT Pancreatic Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2590501763","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590501763?lang=en_us&edition=fundamental","pubTime":"2025-12-12 21:45","pubTimestamp":1765547111,"startTime":"0","endTime":"0","summary":"Amplia Therapeutics Ltd. announced updated results from its ongoing ACCENT trial investigating its FAK inhibitor narmafotinib in combination with gemcitabine and nab-paclitaxel for metastatic pancreatic cancer. An additional confirmed partial response has been recorded, raising the trial's confirmed objective response rate to 35% , compared to the 23% objective response rate reported for gemcitabine and nab-paclitaxel alone in the benchmark MPACT trial. These updated data were presented by Amplia CEO Dr. Chris Burns at the Life Sciences Virtual Investor Forum on December 11.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amplia Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire  on Decem","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL2ZMKlv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","SG9999014021.USD","BK4588","LU2210150020.SGD","LU0314104364.USD","BK4112","IE00B3QW5Z07.USD","LU2095319765.USD","SG9999014005.SGD","SG9999014013.SGD","LU2210149790.SGD","SG9999014039.USD","IE00BGHQF748.EUR","BK4585","IE00BKPKM429.USD","NDAQ","ATX.AU","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2588752041","title":"BRIEF-Amplia Therapeutics Key Narmafotinib Patent Granted In U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=2588752041","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588752041?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:58","pubTimestamp":1764770313,"startTime":"0","endTime":"0","summary":"BRIEF-Amplia Therapeutics Key Narmafotinib Patent Granted In U.S.Dec 3 (Reuters) - Amplia Therapeutics Ltd ATX.AX:AMPLIA THERAPEUTICS LTD: KEY NARMAFOTINIB PATENT GRANTED IN U.S.Source text: ID:nGNX4bMQBbFurther company coverage: ATX.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nFWN3X818F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATX.AU","BK7067"],"gpt_icon":0},{"id":"2588304114","title":"Amplia Therapeutics Ltd: Key Narmafotinib Patent Granted in U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=2588304114","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588304114?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:48","pubTimestamp":1764769733,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nFWN3X818F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ATX.AU"],"gpt_icon":0},{"id":"2588306122","title":"Amplia Therapeutics Secures Key US Patent for Cancer Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2588306122","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588306122?lang=en_us&edition=fundamental","pubTime":"2025-12-03 06:25","pubTimestamp":1764714300,"startTime":"0","endTime":"0","summary":"Amplia Therapeutics  received formal approval from the US Patent and Trademark Office for a patent covering a salt and crystal form of its cancer drug candidate, narmafotinib, being developed clinically, according to a Wednesday Australian bourse filing.The patent, allowed in September, has been granted in major markets such as Europe, Japan, India, Korea, and Australia, securing narmafotinib's protection until at least 2040, with other regions still under review, the filing added.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ATX.AU","LENZ","BK4139","BK4539","BK4007","BK7067"],"gpt_icon":0},{"id":"2586027243","title":"BUZZ-Australia's Amplia Therapeutics falls as HY loss widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2586027243","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586027243?lang=en_us&edition=fundamental","pubTime":"2025-11-28 10:56","pubTimestamp":1764298591,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Amplia Therapeutics falls as HY loss widens** Shares of Amplia Therapeutics ATX.AX fall 3.6% to A$0.135, on track for their weakest session since November 18** The clinical-stage, dru","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nL6N3X4048:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","ATX.AU"],"gpt_icon":0},{"id":"2586488982","title":"BRIEF-Amplia Therapeutics Posts HY Loss Attributable A$4.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2586488982","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586488982?lang=en_us&edition=fundamental","pubTime":"2025-11-27 16:25","pubTimestamp":1764231958,"startTime":"0","endTime":"0","summary":"BRIEF-Amplia Therapeutics Posts HY Loss Attributable A$4.1 MillionNov 27 (Reuters) - Amplia Therapeutics Ltd ATX.AX:HY LOSS ATTRIBUTABLE A$4.1 MILLIONHY REVENUES FROM ORDINARY ACTIVITIES & OTHER INCOME A$2.8 MILLIONFurther company coverage: ATX.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251127:nFWN3X3033:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATX.AU","BK7067"],"gpt_icon":0},{"id":"2586219186","title":"Amplia Therapeutics Ltd -  Hy Revenues From Ordinary Activities & Other Income a$2.8 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2586219186","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586219186?lang=en_us&edition=fundamental","pubTime":"2025-11-27 13:46","pubTimestamp":1764222366,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251127:nFWN3X3033:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ATX.AU"],"gpt_icon":0},{"id":"2586191852","title":"Amplia Therapeutics Ltd - Hy Loss Attributable a$4.1 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2586191852","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586191852?lang=en_us&edition=fundamental","pubTime":"2025-11-27 13:46","pubTimestamp":1764222366,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251127:nFWN3X3033:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ATX.AU"],"gpt_icon":0},{"id":"2578967418","title":"Amplia Therapeutics Ltd-Amplia Receives R&D Tax Rebate Totalling $3.77 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2578967418","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578967418?lang=en_us&edition=fundamental","pubTime":"2025-10-28 06:13","pubTimestamp":1761603205,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251027:nTUE71C3TQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ATX.AU"],"gpt_icon":0},{"id":"2576709239","title":"Amplia Therapeutics Seeks to Uplist to OTCQB Exchange As Part of Efforts to Expand US Presence, Shares Jump 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2576709239","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576709239?lang=en_us&edition=fundamental","pubTime":"2025-10-17 10:50","pubTimestamp":1760669404,"startTime":"0","endTime":"0","summary":"Amplia Therapeutics  plans to expand its US presence, including via a filing to uplist from the Pink Sheet to the OTCQB exchange, according to a Friday Australian bourse filing.The firm is embarking on an expanded capital markets campaign, which includes activities with several financial institutions.The firm's shares jumped 5% in recent trading on the Australian bourse on Friday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","ATX.AU","LENZ","XJO.AU","XKO.AU","BK4539","BK4007","XAO.AU","BK4139"],"gpt_icon":0},{"id":"2574544909","title":"ASX Small-Cap Stocks to Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2574544909","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574544909?lang=en_us&edition=fundamental","pubTime":"2025-10-09 07:40","pubTimestamp":1759966828,"startTime":"0","endTime":"0","summary":"Investors are likely to keep an eye on the following small-cap stocks listed on the Australian Securities Exchange.Winchester Energy (ASX:WEL)Winchester Energy started drilling the JVU-5 production we","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ORR.AU","BK7104","CWX.AU","TAR.AU","WEL.AU","BK7067","AM5.AU","ORR","BK7142","ATX.AU","BK7095"],"gpt_icon":0},{"id":"2571639362","title":"Amplia Therapeutics Says Patent Protecting Cancer Drug Candidate Allowed in US","url":"https://stock-news.laohu8.com/highlight/detail?id=2571639362","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571639362?lang=en_us&edition=fundamental","pubTime":"2025-09-30 08:16","pubTimestamp":1759191387,"startTime":"0","endTime":"0","summary":"Amplia Therapeutics (ASX:ATX) was informed by the US Patent and Trademark Office that a patent describing the specific chemical form of its narmafotinib drug candidate, being used in ongoing clinical ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ATX.AU","LENZ","BK4139","BK4539","BK4007","BK7067"],"gpt_icon":0},{"id":"2564340827","title":"Amplia Therapeutics Says US Council Adopts Name for Cancer Drug Candidate; Shares Fall 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2564340827","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564340827?lang=en_us&edition=fundamental","pubTime":"2025-09-02 11:41","pubTimestamp":1756784464,"startTime":"0","endTime":"0","summary":"Amplia Therapeutics  said the United States Adopted Names Council adopted narmafotinib as the generic name for its inhibitor targeting focal adhesion kinase, a non-receptor protein tyrosine kinase being developed for pancreatic cancer, according to a Tuesday filing with the Australian bourse.A clinical trial of narmafotinib in combination with the folfirinox chemotherapy regimen as a potential treatment for pancreatic cancer will be conducted in the US and Australia, per the filing. The study will assess the treatment candidate's safety, tolerability, and efficacy, among others.Shares of the company fell past 3% in recent Tuesday trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XAO.AU","BK7067","BK4007","XJO.AU","BK4539","XKO.AU","BK4139","ATX.AU","LENZ"],"gpt_icon":1},{"id":"2563060088","title":"ASX Small-Cap Stocks to Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2563060088","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563060088?lang=en_us&edition=fundamental","pubTime":"2025-08-29 07:42","pubTimestamp":1756424546,"startTime":"0","endTime":"0","summary":"Investors are likely to keep an eye on the following small-cap stocks listed on the Australian Securities Exchange.Echelon Resources Echelon Resources reported a net increase in gas reserves across its portfolio, primarily due to a 9% uplift at the Mereenie field, following the end of fiscal year reviews with its joint venture operators.Mitchell Services Mitchell Services said a Sumitomo subsidiary completed a material equity investment in Loop Decarbonisation Solutions. Sumitomo agreed to acquire up to a 25% stake in Loop through the issue of new shares in exchange for cash.Asian Battery Metals Asian Battery Metals confirmed that fourth-phase diamond drilling will begin at its Oval discovery in Mongolia in September.Amplia Therapeutics Amplia Therapeutics said two trial sites in Melbourne and Sydney are now open for its clinical trial exploring the combination of its focal adhesion kinase inhibitor narmafotinib with the chemotherapy FOLFIRINOX in newly diagnosed metastatic pancreatic ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TSO.AU","ECH.AU","BK7104","MSV.AU","AZ9.AU","BK7095","ATX.AU","1OZmain","BK7067","BK7142","BK7506"],"gpt_icon":0},{"id":"2557446823","title":"Amplia Says Pancreatic Cancer Trial Shows Better Results for Drug Candidate in Combination With Chemotherapy; Shares Fall 21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2557446823","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557446823?lang=en_us&edition=fundamental","pubTime":"2025-08-06 11:40","pubTimestamp":1754451642,"startTime":"0","endTime":"0","summary":"Amplia Therapeutics  said data from the ongoing phase 1b/2a clinical trial in the treatment of advanced pancreatic cancer with its focal adhesion kinase inhibitor narmafotinib drug candidate in combination with standard-of-care chemotherapies gemcitabine and Abraxane showed better results when compared with the results of chemotherapy alone, according to a Wednesday Australian bourse filing.The objective response rate for the study is currently at 31%, compared with a 23% response rate for chemotherapy alone.The adverse event profile of the narmafotinib combination is similar to adverse events previously reported for the chemotherapy combination of gemcitabine and Abraxane, in both types of event, rate of occurrence, and severity.Seventeen patients are currently still enrolled in the study, with seven patients having stayed on trial for over 12 months, the filing said. The mean days on trial for evaluable patients is 202 days, compared with the 117 days reported for chemotherapy alone ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ATX.AU","BK7067"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ampliatx.com","stockEarnings":[{"period":"1week","weight":0.3077},{"period":"1month","weight":0.36},{"period":"3month","weight":0.0303},{"period":"6month","weight":-0.5},{"period":"1year","weight":0.8085},{"period":"ytd","weight":0.1333}],"compareEarnings":[{"period":"1week","weight":0.0155},{"period":"1month","weight":0.0306},{"period":"3month","weight":0.0483},{"period":"6month","weight":0.1028},{"period":"1year","weight":0.2634},{"period":"ytd","weight":0.0088}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"description":"Amplia Therapeutics Limited, a pharmaceutical company, focuses on advancing a pipeline of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its clinical development pipeline comprises two lead molecules, AMP945 and AMP886 that inhibits (FAK). The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.04948},{"month":2,"riseRate":0.416667,"avgChangeRate":0.140591},{"month":3,"riseRate":0.416667,"avgChangeRate":-0.013753},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.01631},{"month":5,"riseRate":0.333333,"avgChangeRate":0.147978},{"month":6,"riseRate":0.666667,"avgChangeRate":0.115579},{"month":7,"riseRate":0.583333,"avgChangeRate":-0.015584},{"month":8,"riseRate":0.5,"avgChangeRate":0.034162},{"month":9,"riseRate":0.25,"avgChangeRate":-0.006972},{"month":10,"riseRate":0.25,"avgChangeRate":-0.042445},{"month":11,"riseRate":0.583333,"avgChangeRate":-0.009364},{"month":12,"riseRate":0.538462,"avgChangeRate":0.032423}],"exchange":"ASX","name":"AMPLIA THERAPEUTICS LTD","nameEN":"AMPLIA THERAPEUTICS LTD"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"AMPLIA THERAPEUTICS LTD(ATX.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest AMPLIA THERAPEUTICS LTD(ATX.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"AMPLIA THERAPEUTICS LTD,ATX.AU,AMPLIA THERAPEUTICS LTD股票,AMPLIA THERAPEUTICS LTD股票老虎,AMPLIA THERAPEUTICS LTD股票老虎国际,AMPLIA THERAPEUTICS LTD行情,AMPLIA THERAPEUTICS LTD股票行情,AMPLIA THERAPEUTICS LTD股价,AMPLIA THERAPEUTICS LTD股市,AMPLIA THERAPEUTICS LTD股票价格,AMPLIA THERAPEUTICS LTD股票交易,AMPLIA THERAPEUTICS LTD股票购买,AMPLIA THERAPEUTICS LTD股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"AMPLIA THERAPEUTICS LTD(ATX.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest AMPLIA THERAPEUTICS LTD(ATX.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction